Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

SGNASlayer Dec. 25 at 8:14 AM

$CRVO Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. Absent traction, patience will erode.

0 · Reply

MV0527 Dec. 24 at 1:58 PM

$CRVO The big guys are sitting on a ton of cash.

0 · Reply

MV0527 Dec. 24 at 1:56 PM

$CRVO soon

0 · Reply

MV0527 Dec. 24 at 1:54 PM

$CRVO

0 · Reply

Doki0926 Dec. 24 at 7:15 AM

$CRVO what can we expect?

1 · Reply

MV0527 Dec. 23 at 9:29 PM

$CRVO he's a runner. Run Forest Run

0 · Reply

Dovkav Dec. 23 at 5:12 PM

$CRVO

0 · Reply

MV0527 Dec. 23 at 1:14 PM

$CRVO I also don't believe CervoMed has any issues getting financing if needed. Officers wouldn't have bought shares before deluded share value and zi think their strengths are their contacts in Big Pharma and financial options. Signs are there IMO.

0 · Reply

MV0527 Dec. 23 at 12:50 PM

$CRVO Cantor Fitzgerald coverage along withHC Wainwright is the primary driver right now. This is so undervalued right now. Based on the positive results this should have popped to the 20's already. I can see Cantor moving it there.

0 · Reply

MV0527 Dec. 22 at 9:29 PM

$CRVO no brain swelling with neflamapimod. No MRI needed with neflamapimod.

1 · Reply

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 23 days ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 2 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 2 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 3 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 3 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 5 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 6 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 8 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 9 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 9 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 9 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 10 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 11 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

SGNASlayer Dec. 25 at 8:14 AM

$CRVO Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. Absent traction, patience will erode.

0 · Reply

MV0527 Dec. 24 at 1:58 PM

$CRVO The big guys are sitting on a ton of cash.

0 · Reply

MV0527 Dec. 24 at 1:56 PM

$CRVO soon

0 · Reply

MV0527 Dec. 24 at 1:54 PM

$CRVO

0 · Reply

Doki0926 Dec. 24 at 7:15 AM

$CRVO what can we expect?

1 · Reply

MV0527 Dec. 23 at 9:29 PM

$CRVO he's a runner. Run Forest Run

0 · Reply

Dovkav Dec. 23 at 5:12 PM

$CRVO

0 · Reply

MV0527 Dec. 23 at 1:14 PM

0 · Reply

MV0527 Dec. 23 at 12:50 PM

0 · Reply

MV0527 Dec. 22 at 9:29 PM

$CRVO no brain swelling with neflamapimod. No MRI needed with neflamapimod.

1 · Reply

Disinformation_Consumer Dec. 22 at 9:10 PM

$CRVO I bet partnership/buyout rumors are coming. Volume is way too high for a stock that is going to be diluted.

2 · Reply

Doki0926 Dec. 22 at 6:34 PM

$CRVO joke 4% is shit

0 · Reply

Alien1980 Dec. 22 at 6:33 PM

$CRVO low vol banger poised for the move higher..

0 · Reply

Dovkav Dec. 22 at 5:40 PM

$CRVO

0 · Reply

Dovkav Dec. 22 at 5:23 PM

$CRVO

0 · Reply

justiceforb_85 Dec. 21 at 4:29 AM

$CRVO any possibility of a partner for P3?

1 · Reply

MV0527 Dec. 20 at 4:53 PM

$CRVO

0 · Reply

Messerschmittbf109 Dec. 19 at 7:41 PM

$CRVO analysts seems ….are their friends ..pumping the stocks every day Smell odorous of fifty ..fi f ty

1 · Reply

MV0527 Dec. 19 at 7:27 PM

$CRVO staying the course. Some E.O.Y. selling. Cantor just upgraded.

1 · Reply

Stu_padasso Dec. 19 at 6:37 PM

$CRVO timber frick well i had ample opportunity to get out 5 on horizon

1 · Reply

Messerschmittbf109 Dec. 19 at 6:28 PM

$CRVO Cantor Fitzgerald started covering CervoMed (NASDAQ:CRVO) on Thursday with an Overweight rating. The stock, currently trading at $7.99, appears slightly undervalued according to InvestingPro's Fair Value estimates, with analyst price targets ranging from $15 to $31 And these others cl…

0 · Reply

Messerschmittbf109 Dec. 19 at 6:13 PM

$CRVO they have done just a giant pump in march and then a long distribution… … they made their gain months ago

0 · Reply

Market Cap	77.91M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	20,800
Avg Vol	70,828
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	94%
Beta	-0.91
Analysts	Strong Sell
Price Target	$22.43